Skip to main content

Table 3 Overall tophus complete response in patients over time during the randomized controlled trials a

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Variables

Pegloticase

Pegloticase

Placebo

 

biweekly

monthly

 

(n= 62)

(n= 64)

(n= 29)

Week 13

 Patients with evaluable tophi at visit, n

46

48

25

 CR, n (%)

10 (22)

4 (8)

0

 P valueb

0.011

0.292

–

Week 25

 Patients with evaluable tophi at visit, n

40

39

24

 CR, n (%)

18 (45)

10 (26)

2 (8)

 P valueb

0.002

0.110

–

Final visitc

 Patients with evaluable tophi, n

52

52

27

 CR, n (%)

21 (40)

11 (21)

2 (7)

 P valueb

0.002

0.200

–

  1. aCR, complete response. bPegloticase groups versus placebo for CR. cFinal visit includes data from the patient’s final visit, whenever it occurred, for all evaluable completers and noncompleters.